ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

Letters to the Editor: Us Too! Objects to ODAC Member’s Comments; Brawley Responds

March 28, 2003

Mammography’s Best Role Is Screening, Kopans Assert

March 18, 1994

New NCI Grant Program Will Support Young Scientists In Innovative, “Risky” Research

May 27, 1977

Avastin Loses Indication for Breast Cancer

November 18, 2011

GSK’s Votrient Approved For Advanced Kidney Cancer

October 30, 2009

Dramatic Increase In Third World Cancer Rates May Face National, International Organizations: Murphy

September 17, 1982